Muscle Fatigue and Carbonic Anhydrase Inhibitors

The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02758470

Enrollment

Registered

2016-05-02

Start date

2016-11-30

Completion date

2017-06-30

Last updated

2018-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxia

Keywords

Muscle Fatigue, Acetazolamide, Methazolamide

Brief summary

The objective of this research is to assess the effects of acetazolamide and methazolamide on respiratory and limb muscle fatigue development. A fatiguing protocol will be conducted for the respiratory and plantar flexor muscles and the difference in pressure/torque produced by supramaximal nerve stimulation used to assess muscle fatigue between conditions.

Interventions

DRUGAcetazolamide

250 mg, taken orally three times per day

DRUGMethazolamide

100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.

OTHERPlacebo

A placebo will be taken three times per day

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Age: 18-40 years. * Regularly physically active * Male

Exclusion criteria

* current or ex-smokers * pulmonary function \<80% of predicted * esophageal tumour or ulcer * have had recent (\<6 months) musculoskeletal injury or any surgery to the lower leg * have contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma, adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa allergy or an electrolyte imbalance such as hyperchloremic acidosis) * are obese (BMI \>30 Kg/m2) * taking diuretics, blood thinners, or anti-platelet drugs.

Design outcomes

Primary

Measure	Time frame
Change in trans-diaphragmatic pressure generation to supramaximal phrenic nerve stimulation following inspiratory threshold loading.	Baseline, 1, 5, 10, 20, and 30 minutes following the loading protocol for each arm of the study
Change in plantar flexor muscle group torque generation to supramaximal tibial nerve stimulation following an isometric loading protocol	Baseline, 1, 5, 10, 20, and 30 minutes following the loading protocol for each arm of the study

Secondary

Measure	Time frame
Maximal Voluntary Contraction of the Plantar Flexor Muscle Group	Baseline and immediately following the loading protocol
Maximal inspiratory pressure maneuvers	Baseline and immediately following loading protocol
Contraction time and half-relaxation time	Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol

Other

Measure	Time frame
Heart Rate	Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol
Beat-by-beat blood pressure	Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol
Esophageal and Gastric Pressure	Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026